Titlebook: In Vivo Imaging of Cancer Therapy; Anthony F. Shields,Pat Price Book 2007 Humana Press 2007 Tumor.agents.cancer treatment.clinical researc

條約

HALO

Estrogen-Receptor Imaging and Assessing Response to Hormonal Therapy of Breast Cancer,e not responding to the selected therapy shortly after starting treatment, so that an alternative therapy can be initiated. The traditional criteria for assessing therapeutic response in breast cancer are based on changes in size of measurable disease or on decline of tumor markers. Unfortunately, t

FLAIL

Positron Emission Tomography Measurement of Drug Kinetics,n this review, basic principles of PET drug kinetic measurement techniques are discussed, followed by examples of PET kinetic studies performed at various stages of the drug developmental process and their utility and contribution to anticancer drug development are highlighted.

Sad570

, Magnetic Resonance Spectroscopy in Clinical Oncology,often the major modality in the imaging of cancer patients. In routine clinical practice MR is commonly used to obtain anatomical information, but this technique is very versatile and offers many possibilities to acquire more functional information, in particular, information of a physiological and

薄膜

獎(jiǎng)牌

Imaging of Apoptosis,uld be very helpful to have an . imaging technique. Characteristic changes of apoptosis can be identified by ultrasound, magnetic resonance, and radionuclide approaches. The status of these approaches is outlined in this chapter with possible clinical uses listed in Table 1.

不適當(dāng)

AUGUR

Anatomical Measure of Tumor Growth with Computed Tomography and Magnetic Resonance Imaging,imes to be undertaken. Most chemotherapeutic agents currently on the market are cytotoxic, with a low therapeutic index, and act on rapidly dividing cells making no distinction between malignant cells and normal rapidly dividing cells such as the gastrointestinal tract and bone marrow.

nitroglycerin

情感脆弱

Imaging Genes for Viral and Adoptive Therapies,t appropriate tissues and deliver therapeutic genes to a sufficient number of target cells, the inability to monitor the level of expression of the therapeutic gene, the loss of therapeutic gene expression over time, and the inability to correlate the level and duration of gene expression with therapeutic outcome.